Siamak Daneshmand hosts Trinity Bivalacqua to discuss advancements in non-muscle invasive bladder cancer, particularly focusing on newly FDA-approved therapies. Dr. Bivalacqua highlights the excitement surrounding the approval of new treatments for BCG unresponsive bladder cancer, including pembrolizumab and nadofaragene (ADSTILADRIN). He explains the significance of these developments, particularly nadofaragene, the first gene therapy in bladder cancer, which shows promising efficacy and tolerability. The conversation also touches on the challenges of delivering current treatments like gem-docetaxel in community settings and the potential of nadofaragene to overcome these hurdles due to its ease of administration. They conclude by discussing the future of bladder cancer treatment, emphasizing the importance of new clinical trials and the evolving landscape of therapy sequencing and combination treatments.

Biographies:

Trinity Bivalacqua, MD, PhD, The University of Pennsylvania, Philadelphia PA

Siamak Daneshmand, MD, Associate Professor of Urology (Clinical Scholar), Director of Clinical Research, Keck School of Medicine, University of Southern California, Los Angeles, CA

Related Content:

Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial.


Gene Therapy for NMIBC: A New Era of Treatment - Colin Dinney

New Data Show Durable Response Following Treatment with ADSTILADRIN® (nadofaragene firadenovec-vncg)


FDA Approves First Gene Therapy for the Treatment of High-Risk, Non-Muscle-Invasive Bladder Cancer